— Advancing pipeline of synthetic-lethal, precision oncology therapies for multiple solid tumor indications — — Financing supports initiation of two novel compounds into the clinic in the next 18 months — CAMBRIDGE, Mass. & MONTREAL, September 4, 2019-- Repare Therapeutics, a precision oncology company targeting specific vulnerabilities of tumors in genetically defined patient populations, announced today the completion of a US$82.5 million Series B financing. Cowen Healthcare Investments led the financing and was joined by new investors OrbiMed, Redmile, BVF Partners L.P. and Logos Capital.